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Abstract
In this short communication, a novel fatty acid-binding protein 5 (FABP5)-related signal transduction pathway in
prostate cancer is reviewed. In castration-resistant prostate cancer (CRPC) cells, the FABP5-related signal trans-
duction pathway plays an important role during transformation of the cancer cells from androgen-dependent
state to androgen-independent state. The detailed route of this signal transduction pathway can be described
as follows: when FABP5 expression is increased as the increasing malignancy, excessive amounts of fatty acids
from intra- and extra-cellular sources are transported into the nucleus of the cancer cells where they act as
signalling molecules to stimulate their nuclear receptor peroxisome proliferator-activated receptor gamma
(PPARγ). The phosphorylated or biologically activated PPARγ then modulates the expression of its downstream
target regulatory genes to trigger a series of molecular events that eventually lead to enhanced tumour expan-
sion and aggressiveness caused by an overgrowth of the cancer cells with a reduced apoptosis and an increased
angiogenesis. Suppressing the FABP5-related pathway via RNA interference against FABP5 has produced a
63-fold reduction in the average size of the tumours developed from CRPC cells in nude mice, a seven-fold
reduction of tumour incidence, and a 100% reduction of metastasis rate. Experimental treatments of CRPC with
novel FABP5 inhibitors have successfully inhibited the malignant progression of CRPC cells both in vitro and
in nude mouse. These studies suggest that FABP5-related signal transduction pathway is a novel target for
therapeutic intervention of CRPC cells.
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Fatty acid-binding protein 5 (FABP5) is a member of
the fatty acid binding protein family that is responsible
for transporting fatty acids between intracellular and
extracellular membranes. FABP5 is a 15 kDa cytosolic
protein, which binds with a high affinity to medium and
long chain fatty acids.1 Overexpression of FABP5 at the
mRNA level was initially detected by specific molecular
approaches developed for a systematic analysis of differ-
ential gene expression between benign and malignant
human prostate epithelial cells.2–4 Using a ‘subtractive
selection’ strategy combined with some other methods,5
a number of novel genes whose alternated expressions
are involved in the malignant changes of the prostate
cancer cells have been identified. Among them, FABP5
is the one studied most. After the FABP5 mRNA was
identified as an upregulated gene in prostate cancer
by differential expression analysis,6 the difference was
further confirmed with Northern and slot blot analyses
that showed that the expression levels of FABP5 mRNA
in prostate cancer cell lines were increased by up to
17-fold from the benign epithelial cell line. At the
protein level, the difference between the benign and
the cancer cell lines was similar to that detected at
the mRNA level. The level of FABP5 mRNA in prostate
carcinoma tissues was significantly higher than that
in the benign prostatic hyperplasia (BPH) by in situ
hybridization. When the functional role of the increased
FABP5 was characterized by gene transfection with
the benign, non-metastatic rat Rama37 model,7 the
forced expression of FABP5 in Rama37 cells produced
metastasis in a significant (23% of the rats) number
of animals, whereas no metastasis was produced in
the control group. Both FABP5 mRNA and protein were
overexpressed in the pool of FABP5-transfectants and
in the sublines established from their metastases,
no FABP5 was detected in the control transfectants.
Immunocytochemical staining showed that FABP5 was
expressed in both the primary tumours developed from
the FABP5 transfectants and their metastases, it was not
expressed in the primary tumours developed from the
control that did not produce metastasis. Re-inoculation
of the sublines established from metastases in Rama37
caused 50% of animals with metastases, which is higher
than that obtained in the first-round inoculations.
This result suggests that the metastatic clones have
been preferentially selected from the original pool
of a mixture of both metastatic and non-metastatic
transfectant clones. When an archival set of prostate
tissues was assessed,8 both nuclear and cytoplasmic
FABP5 levels in carcinoma cells were significantly higher
than those in normal and BPH tissues. The increased
FABP5 was significantly associated with a reduced
patient survival time. Thus, it was concluded that FABP
was ametastasis-inducing gene and it promotes tumori-
genicity and metastasis of cancer cells under suitable
conditions.
FABP5-related signal transduction path-
way in CRPC cells
Investigation of the molecular mechanisms involved in
tumour-promoting activity of FABP5 has established that
there is a fatty acid–initiated signalling pathway lead-
ing to malignant progression of prostatic cancer cells.
Demethylation of the promoter region of FABP5 gene in
CRPC cells causes a large-scale increase in FABP5 expres-
sion.9 Increased FABP5 expression plays a crucial role
in this novel signalling pathway. When FABP5 expres-
sion is increased, large amounts of fatty acids are trans-
ported into the cancer cells and used as new sources
of energy to meet the need of the quick cell growth.
Excessive amounts of fatty acids are transported into
the nucleus where they act as signalling molecules to
stimulate their nuclear receptor peroxisome proliferator-
activated receptor gamma (PPARγ). The activated PPARγ
then regulates the expression of its downstream genes
to cause a chain of molecular events that eventually
lead to an enhanced tumour expansion and an increased
aggressiveness resulting from a reduced apoptosis and
an increased angiogenesis.10–13
Recently, expression of FABP5, PPARβ/δ and PPARγ has
been measured in prostate cell lines, BPH and prostatic
carcinomas to assess the correlation between FABP5 and
either of the nuclear fatty acid receptors. The levels of
both FABP5 and PPARγ in prostate cancer cell lines are
significantly higher than that in the benign cells. Their
cytoplasmic and nuclear expressions are significantly
increased in carcinomas than that in BPH tissues. The
increased levels of FABP5 and PPARγ are both signifi-
cantly correlated to the increased joint Gleason scores
(GS) of the cases and are significantly associated with
a reduced patient survival time. The same study also
showed that the enhanced expression of cytoplasmic
FABP5 significantly correlated with an increased nuclear
PPARγ, but not related to the level of cytoplasmic PPARγ.
The expression of PPARβ/δ in carcinomas neither corre-
lates with patient outcomes, nor associates with cyto-
plasmic or nuclear FABP5 level.Multivariate analysis sug-
gested that FABP5 was independently associated with
patient survival times, whereas PPARγ was confounded
by FABP5 in predicting patient survival times. Thus, both
FABP5 and PPARγ are suitable as prognostic factors to
predict the survival of patients with prostate cancer. The
increased FABP5 interacts with PPARγ in a coordinated
manner to promote malignant progression of the cancer
cells.11
To understand how the activated PPARγ regulates
its downstream possible cancer-promoting or tumour-
suppressing genes, a study was conducted to investigate
the molecular mechanisms involved in PPARγ’s tumour-
promoting role in prostate cancer. Suppression of PPARγ
in highly malignant PC3-M cells produced a significant
reduction in the cell proliferation rate by up to 53%. It
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inhibited the invasiveness by up to 89%, and reduced
the number of colonies formed in soft agar by up
to 94%. Knockdown of PPARγ gene in PC3-M cells
by siRNA significantly reduced tumour incidence in
nude mice by 90%, the average tumour size by 99%,
and prolonged the latent period significantly 3.5-fold.
Results in this study combined with results from some
previous studies suggested that FABP5 promoted VEGF
expression and facilitated angiogenesis through PPARγ
that was activated by the simulation of the fatty acids
transported by FABP5. Further investigations showed
that upregulatedVEGF expression by PPARγwas achieved
through binding to the PPAR-responsive elements in the
promoter region of the VEGF gene in the cancer cells.
Evidence also shows that androgen receptor (AR) can
modulate VEGF expression through the Sp1/Sp3 binding
site on the VEGF promoter in the cancer cells, this route,
replaced gradually by the FABP5-PPARγ-VEGF signal
pathway,was disappeared as the cells gradually lost their
androgen dependency. These results demonstrated that
the FABP5-PPARγ-VEGF signal transduction axis is amore
important novel therapeutic target for angiogenesis-
suppression treatment of CRPC than the androgen
regulated route.14 It is possible that AR-initiated pathway
plays an important role in androgen-dependent cancer
cells, but the role of FABP5-related pathway increases
gradually as themalignancy of the cancer cells increases,
until it completely replaces the AR-initiated pathway
when the cancer cells become completely androgen-
independent. The growth and expansion of prostate
cancer depend on androgen stimulation in the early
stage. During androgen-deprivation therapy (ADT),
the AR-initiated pathway is suppressed, cancer cells
are subjected to high selection pressure, and most of
them die. Under ADT conditions, some cancer cells
may try to select for new sources of energy supply
and some of these cells have survived ADT because
they have successfully switched their energy source
to fatty acids (fat degradation products). The FABP5-
related pathway now replaces the AR-initiated pathway
gradually with increasing malignancy or androgen-
independency, and becomes the dominant pathway in
AR-negative, androgen-independent CRPC cells. Thus,
inhibiting the FABP5-related signal pathway is essential
for the suppression of themalignant progression of CRPC
cells.10,14 This model is very different from our previous
understanding of the molecular mechanisms of how
CRPC cells are transformed from androgen-dependent
to independent status.15
Potential as a target for therapeutic inter-
vention
A number of experimental treatments have been con-
ducted on suppression of tumorigenicity and metastatic
ability of the CRPC cells via inhibiting PPARγ, and some
encouraging results have been summarized by two
recent reviews.16,17 To test the therapeutic potential
of targeting FABP5, a new cell line Si-clone-2 was
established by using siRNA to interfere with FABP5
expression in highly malignant PC3-M cells. Suppression
of FABP5 in highly malignant PC3-M cells significantly
inhibited their proliferation and tumorigenicity in vitro.
When the FABP5-suppresed cell line Si-clone-2 was
tested in nude mice, only two out of 13 mice developed
very small primary tumours, with an average size of
23 mg, without any metastases. But all 14 mice in
the control group developed primary tumours with
an average size of 1450 mg, and 64.3% (9/14) animals
produced metastasis. When inoculated subcutaneously,
all five mice in the control group developed tumours
from day 4, with an average size of 1471 mm3 at 5 weeks
after the inoculation; whereas Si-clone-2 cells produced
no tumours at any time-point in any of the five animals,
indicating the suppression occurred at the initiation
stage. Thus the internally transcribed siRNA within cells
produced a 63-fold reduction in average tumour size,
seven-fold reduction in tumour incidence, and 100%
reduction in metastasis rate.8 To test whether siRNA to
FABP5 delivered to the external environment of a CRPC
would suppress tumorigenicity in vivo, experiments were
established whereby siRNA to FABP5 suspended in a
RNA-stabilizing substance atelocollagen was injected
around tumour masses produced by PC3-M cells in
nude mice and compared to the effect of injections
of non-specific scrambled siRNA in atelocollagen. At
autopsy, the average size of tumours from the groups
treated with 10 and 15 μM siRNA in atelocollagen was
significantly smaller by more than three-fold that of
the control. These data demonstrate that FABP5 siRNA
delivered by atelocollagen to the external environment
surrounding a tumour mass can effectively inhibit the
CRPC cell growth in nude mice. However, using siRNAs
directly as treatment reagents is much less effective
than the internally transcribed siRNA, it can only slow
down, rather than stop the tumour growth. Furthermore,
stabilizing agent atelocollagen (a cow skin extract) is too
expensive to be available in routine supply.18
A recent experimental CRPC treatment by suppressing
the FABP5-related pathway has been conducted by
direct application of a chemical inhibitor SB-FI-26 to
suppress the biological activity of FABP5.19 SB-FI-26
can significantly suppress the invasiveness, migration,
proliferation, and the anchorage-independent growth of
PC3-M cells in vitro. It suppressed the metastatic rate by
50% and the average primary tumour mass developed
from the prostate gland of the nude mice by nine-fold.
The inhibitor SB-FI-26 competitively binds to FABP5
to inhibit the fatty acid uptake by the cancer cells,
and hence avoids fatty acid stimulation of PPARγ. This
prevents PPARγ activating the downstream regulated
cancer-promoting genes. SB-FI-26 is, in fact, the main
component of the Chinese traditional herbal medicine
incarvillea sinensis, which has been used as an analgesic
to treat rheumatism for hundreds of years.20 It has
been suggested to be a candidate for development of
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anti-inflammatory and anti-nociceptive drugs.21 The
main problem in using SB-FI-26 as an experimental
therapeutic agent for CRPC is the issue of dosage. For
achieving the optimal effect, the dose (>100 μM) required
is too high to be practical to maintain a sufficient supply.
How to increase its effect and hence to reduce the dose of
SB-FI-26 needed for CRPC treatment is a new challenge.
More recently, a highly efficient recombinant FABP5
inhibitor, named dmrFABP5, has been produced to con-
duct experimental treatment of CRPC.22 Treatment with
dmrFABP5 significantly suppressed the proliferation,
migration, invasion and soft agar colony formation of
the highly malignant CRPC cells PC3-M in vitro. To test
dmrFABP5’s suppressive effect on CRPC, the human PC3-
M cells were implanted orthotopically into the prostate
gland of immunosuppressed nude mice to produce
tumours. Treatment with dmrFABP5 has produced a
highly significant inhibition of 100% in metastatic rate
and a highly significant reduction of 13-fold in the
average size of primary tumours. Immunocytochemical
analysis showed that the staining intensity of dmrFABP5
treated tumours was reduced by 67%. Similar to SB-FI-
26, dmrFABP5 suppressed the cancer cells by blocking
fatty acid stimulation of PPARγ, and thereby prevented
it activating downstream genes. The difference between
dmrFABP5 and SB-FI-26 is that dmrFABP5 did not bind
to FABP5 to suppress the cellular fatty acid uptakes.
Thus, more study is required to understand exactly how
dmrFABP5 suppressed PPARγ. The novel FABP5 inhibitor
dmrFABP5 is the most effective molecule discovered so
far for experimental treatment of CRPC and its inhibitory
effect is much greater than that produced by SB-FI-26.
Discussion
We have shown that the FABP5-related signal pathway is
a newly identified signal transduction route in CRPC cells
and the evidence in experimental treatment showed
that suppressing this pathway can effectively inhibit
the malignant progression of the CRPC cells. Although
no clinical trial has been conducted yet in human
patients to study the treatment effect of the inhibitors
of the FABP5-related pathway, it is reasonable to believe
that at least some of this pathway inhibitors are well
tolerated in human body and can act effectively as
drugs. This optimistic view is based on the fact that the
FABP5 inhibitor truxillic acid is the main component
of the herbal medicine incarvillea sinensis, which was
used as an analgesic to treat rheumatism in traditional
medicine,20 and it is also a candidate for development of
anti-inflammatory and anti-nociceptive drugs.21 Thus,
this pathway is a possible novel target for therapeutic
intervention. It must be emphasized, however, that
CRPC is a complicated disease and it may contain many
different, yet currently unknown subtypes, including a
mixture of FABP5-positive, FABP5-negative, AR-positive,
and AR-negative cases. Thus, a personalized medicine
approach will have to be undertaken for each patient
to identify into which of these four possible classes
individual tumours will fall. These classes can be
relatively easily identified from immunohistochemical
analysis of standard pathological specimens of the
primary tumours. However, in the initial stages it will
be necessary to relate their presence to their functional
capability. Thus, primary cultures of each of these four
prostate cancer subtypes will have to be obtained and
tested with inhibitors of the FABP-dependent and AR-
dependent pathways singly and in combination to
ascertain how the individual patient’s prostate cancer
cells will respond to treatment. It may be that the single
inhibitors will only be required for the pure FABP5-
positive and AR-positive groups, whereas a combination
of both inhibitors may be required for the mixed group
and neither inhibitor either singly or in combination
may be useful in the purely negative group. Thus, more
work is needed to clarify whether the FABP5-related
pathway exists in only a proportion of CRPC cases, or
in all CRPC cases, before true clinical trials of inhibitors
to this pathway can be undertaken.
Since FABP5has been identified as a cancer-promoting
molecule in prostate cancer,6,12 subsequent studies have
shown that increased FABP5 expression is now associ-
ated with most23–27 commonly occurring human cancers.
It will be interesting to know whether suppressing the
FABP5-related pathway can also inhibit the progression
of other FABP5-positive cancers so generalizing the
concept and approach beyond that of prostate cancer.
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